Multiple sclerosis and related disorders · 2026
Prevalence of autoimmune comorbidities in aquaporin 4-immunoglobulin G positive neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weng Ninglu, Randhawa Aikjot, Sayfee Karen, Chertcoff Anibal, Marrie Ruth Ann, Varela Lucia B
Аннотация
BACKGROUND: Autoimmune comorbidities in aquaporin-4-immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) may be associated with increased disease severity and therapeutic challenges, yet prevalence estimates vary considerably. Some variability may reflect differences in population characteristics, geography, health systems, and methodology.
OBJECTIVES: To estimate the prevalence of autoimmune comorbidities in AQP4-IgG-positive NMOSD.
METHODS: We searched MEDLINE, Embase, Cochrane CENTRAL, Global Health, and Global Index Medicus for studies published from inception up to November 13, 2025. Four reviewers independently screened and extracted data in duplicate. Eligible studies were published since 2005 and reported autoimmune comorbidity prevalence among people with AQP4-IgG-positive NMOSD. Pooled proportions with 95% confidence intervals (CIs) were estimated using generalized linear mixed models with random effects. Subgroup analyses examined variation by continent and gross national income classification. We assessed study quality using the Joanna Briggs Institute Critical Appraisal Tool. We assessed publication bias by visually inspecting a funnel plot.
RESULTS: Seventy studies encompassing 7843 participants were included. The pooled prevalence of at least one autoimmune comorbidity was 22.2% (95% CI, 19.3-25.3, I2 = 78%). Sjögren's syndrome was most frequent (4.6%), followed by systemic lupus erythematosus (SLE) (3.0%) and autoimmune thyroid disease (2.6%). Prevalence varied by region (Europe, 31.1%; North America, 23.9%; South America, 21.9%; Asia, 16.8%) and by income group (high-income, 25.1%; lower-middle-income, 7.0%).
CONCLUSION: Autoimmune comorbidities were frequently documented in AQP4-IgG-positive NMOSD. Estimates should be interpreted cautiously because ascertainment methods were heterogeneous and validated diagnostic criteria were infrequently reported. Regional differences may reflect population, ascertainment, and healthcare-system factors.
OBJECTIVES: To estimate the prevalence of autoimmune comorbidities in AQP4-IgG-positive NMOSD.
METHODS: We searched MEDLINE, Embase, Cochrane CENTRAL, Global Health, and Global Index Medicus for studies published from inception up to November 13, 2025. Four reviewers independently screened and extracted data in duplicate. Eligible studies were published since 2005 and reported autoimmune comorbidity prevalence among people with AQP4-IgG-positive NMOSD. Pooled proportions with 95% confidence intervals (CIs) were estimated using generalized linear mixed models with random effects. Subgroup analyses examined variation by continent and gross national income classification. We assessed study quality using the Joanna Briggs Institute Critical Appraisal Tool. We assessed publication bias by visually inspecting a funnel plot.
RESULTS: Seventy studies encompassing 7843 participants were included. The pooled prevalence of at least one autoimmune comorbidity was 22.2% (95% CI, 19.3-25.3, I2 = 78%). Sjögren's syndrome was most frequent (4.6%), followed by systemic lupus erythematosus (SLE) (3.0%) and autoimmune thyroid disease (2.6%). Prevalence varied by region (Europe, 31.1%; North America, 23.9%; South America, 21.9%; Asia, 16.8%) and by income group (high-income, 25.1%; lower-middle-income, 7.0%).
CONCLUSION: Autoimmune comorbidities were frequently documented in AQP4-IgG-positive NMOSD. Estimates should be interpreted cautiously because ascertainment methods were heterogeneous and validated diagnostic criteria were infrequently reported. Regional differences may reflect population, ascertainment, and healthcare-system factors.